Zhejiang Hisun Pharmaceutical Co Ltd: A Snapshot of Recent Performance and Overview
Zhejiang Hisun Pharmaceutical Co., Ltd., a prominent player in the health care sector, has recently been in the spotlight due to its performance on the Shanghai Stock Exchange. As of July 8, 2025, the company’s close price stood at 11.32 CNH, with a 52-week high of 11.54 CNH recorded on the same day. The 52-week low for the company was 6.95 CNH, observed on September 17, 2024. The company’s market capitalization is currently valued at 11.6 billion CNH, reflecting its significant presence in the pharmaceutical industry.
Founded in 2000 and publicly listed on the Shanghai Stock Exchange on July 5, 2000, Zhejiang Hisun Pharmaceutical has established itself as a key manufacturer of a diverse range of pharmaceutical products. The company’s portfolio includes anticancer drugs, cardiovascular medicines, anti-parasitics, and anti-infective products. Beyond manufacturing, Zhejiang Hisun Pharmaceutical also offers related pharmaceutical solution services, catering to a broad spectrum of healthcare needs.
The company’s financial metrics indicate a price-to-earnings ratio of 20.26, suggesting investor confidence in its growth potential and profitability. As a leading entity in the pharmaceutical sector, Zhejiang Hisun Pharmaceutical continues to focus on innovation and expansion, aiming to enhance its product offerings and market reach.
For more detailed information about Zhejiang Hisun Pharmaceutical Co., Ltd., including its product range and services, interested parties can visit the company’s official website at www.hisunpharm.com .